Cessatech A/S

Equities

CESSA

DK0061411964

End-of-day quote NORDIC GROWTH MARKET Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
5.98 ^DKK	+2.05%		-.--%	-17.63%

27/05	Cessatech A/S Reports First Patient Dosed in Final Safety Study 0202 of Lead Product Candidate CT001	CI
15/05	Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

First Quarter Report Q1-2024

May 15, 2024 at 12:16 pm IST

Cessatech A/S ("Cessatech" or the "Company") today releases its results for the period 1 January - 31 March 2024. The first quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports.

First quarter financial results 2024 (1 January - 31 March): 

Net revenue was KDKK 0
Operating result was KDKK -4.079
Net result was KDKK -2.711
Cash at bank end of the period was KDKK 15.041
Earnings per share* was KDKK -0,16
Solidity** was 95%

The Company has advanced well with its planned activities

US planning & preparation for CT001 launch
CT001 device verification completed
Study 0202 initiation visits and supply of IMP medicine
Submission of abstract for unified PK-PD model in children

*Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 31 March 2024 amounted to 17.425.094 shares, the average number of shares during the first quarter was 16.602.837
**Solidity: Total equity divided by total capital and liability

Comment from CEO, Jes Trygved:
Our focus has also very much been on the planning and preparation for the US launch of CT001 where we expect to have first packs shipped to selected US hospitals under the Early Access Program in just a few months. Thanks to teams for its efficiency, hard work and commitment for making this possible. We are also pleased to soon initiate the Paediatric Safety Study 0202, which is the final clinical trial before we can prepare for regulatory submission for CT001, and we have submitted an abstract on the paediatric population data, a PK-PD model, which will be presented end of June at a conference in Europe.

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, easy administration, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development, and CT002 is at the early development phase.

https://news.cision.com/cessatech/r/first-quarter-report-q1-2024,c3981692

https://mb.cision.com/Main/19921/3981692/2797662.pdf

Latest news about Cessatech A/S

Cessatech A/S Reports First Patient Dosed in Final Safety Study 0202 of Lead Product Candidate CT001	27/05	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16/11	CI
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children	25/23/25	CI
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001	21/23/21	CI
Cessatech Wins EU Nod for Clinical Studies of Nasal Sedation Spray in Children; Shares Soar 21%	12/23/12	MT
Cessatech A/S Announces EMA's Paediatric Committee Agrees to Paediatric Investigational Plan for CT002 for Procedural Sedation	12/23/12	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/23/24	CI
Cessatech A/S Secures DKK 5 Million Loan Facility Agreement to Support the US Launch of its Lead Program CT001	17/23/17	CI
Cessatech A/S and Ventis Pharma Announce US Partnership for CT001	27/23/27	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	30/23/30	CI
Cessatech A/S Appoints Martin Olin as the Chairman of the Board	23/23/23	CI
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	01/23/01	CI
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI
Cessatech A/S Auditor Raises 'Going Concern' Doubt	28/23/28	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	18/22/18	CI
Cessatech to Raise $2 Million in Rights Offer	14/22/14	MT
Cessatech Reports Successful Outcome of Pharmacokinetic Trial in Children of Lead Candidate	23/22/23	CI
Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate	05/22/05	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	19/22/19	CI
Cessatech A/S Announces Pivotal Trial 0205 Has Obtained Regulatory Approval	30/22/30	CI
Cessatech Reports Last Patient Dosed in Pharmacokinetic Trial in Children of Lead Candidate	16/22/16	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	19/22/19	CI
Cessatech A/S Announces Board Changes	17/22/17	CI

Chart Cessatech A/S

Duration

Period

More charts

Company Profile

Sector

More about the company

Income Statement Evolution

More financial data